Oblimersen Bcl-2 antisense: Facilitating apoptosis in anticancer treatment

Antisense and Nucleic Acid Drug Development

Volumn 12, Issue 3, 2002, Pages 193-213

  Klasa, Richard J ^a   Gillum, Amanda M ^b   Klem, Robert E ^b   Frankel, Stanley R ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b Genta Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DACARBAZINE; DAUNORUBICIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IMATINIB; IMMUNOMODULATING AGENT; IRINOTECAN; MESSENGER RNA; OBLIMERSEN; PACLITAXEL; PROTEIN BCL 2; RITUXIMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ASTHENIA; BLADDER CANCER; BREAST CANCER; CANCER GRAFT; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON CANCER; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG POTENTIATION; DRUG TOLERABILITY; FEVER; HUMAN; HYPOTENSION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MERKEL CELL TUMOR; MOUSE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RNA BINDING; RNA DEGRADATION; RNA TRANSLATION; SCID MOUSE; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA; APOPTOSIS; DRUG EFFECT; GENETICS; NUCLEOTIDE SEQUENCE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER;

EID: 0035992688     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729002760220798     Document Type: Review

References (124)

1. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice
2. Bcl-2 antisense (Genasense™) induces apoptosis and potentiates activity of both cytotoxic chemotherapy and rituximab in primary CLL cells
3. In vivo electroporetic transfer of Bcl-2 antisense oligonucleotide inhibits the development of hepatocellular carcinoma in rats
4. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA
5. High performance liquid chromatographic analysis of phosphorothioate analogues of oligodeoxynucleotides in biological fluids
6. Caspase involved synergistic cytotoxicity of Bcl-2 antisense oligonucleotides and adriamycin on transitional cell cancer cells
7. Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl)all-trans retinamide
8. Bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi
9. Phase III multicenter randomized trial of the Dartmouth regimen versus decarbazine in patients with metastatic melanoma
10. A phase I study of Bcl-2 antisense G3139 (Genta) and weekly docetaxel in patients with advanced breast cancer and other solid tumors
11. Apoptosis-antagonizing protein Bcl-2 expression, distribution in non-Hodgkin's lymphoma and its clinical significance
12. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer
13. Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression
14. Antisense therapy for malignancy
15. Human Bcl-2 antisense therapy for lymphomas
16. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of bcl-2 antisense (Genasense) and docetaxel (D) in hormone refractory prostate cancer
17. Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides
18. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells
19. The effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein expression and apoptosis in human bladder transitional cell carcinoma
20. Prognostic factors for survival of patients treated systemically for disseminated melanoma
21. Phase III trial of dacarbazine versus decarbazine with interferon α2b versus dacarbazine with tamoxifen versus decarbazine with interferon α2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Group study
22. Prognostic significance of Bcl-2 protein expression and bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma
23. Bcl-2 antisense oligonucleotides (ASO) enhances apoptosis and cytotoxicity in drugresistant myeloma cells
24. Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells
25. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides
26. Bcl-2 family members and the mitochondria in apoptosis
27. Bcl-2 expression in malignant melanoma and its prognostic significance
28. Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice
29. Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia
30. Bcl-2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell line
31. Bcl-2 inhibition in the treatment of cancer: Clinical studies with the bcl-2 antisense oligonucleotide G3139
32. Prognostic significance of Bcl-2 protein expression in aggressive non-Hodgkin's lymphoma
33. Prognostic significancer of bcl-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British National Lymphoma Investigation study
34. Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries
35. Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries
36. Bcl-2 plays a major role in resistance to dexamethasone-induced apoptosis in multiple myeloma cell lines
37. Inhibition of thymidine kinase gene expression by antisense RNA: A molecular approach to genetic analysis
38. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
39. Clinical, pharmacologic, and pharmacodynamic study of Genasense (G3139, Bcl-2 antisense oligonucleotide) and dacarbazine (DTIC) in patients with malignant melanoma
40. Chemosensitisation of malignant melanoma by bcl2 antisense therapy
41. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas
42. Manipulation of differentially expressed genes such as bcl-2 leads to increased killing of B chronic lymphocytic leukemia
43. bcl-2 deficiency in mice leads to pleiotropic abnormalities: Accelerated lymphoid cell death in thymus and spleen, polycystic kidney, hair hypopigmentation, and distorted small intestine
44. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia
45. Investigations of antisense oligonucleotides targeted against bcl-2 RNAs
46. Eradication of human non-Hodgkin's lymphoma in SCID mice by Bcl-2 antisense oligonucleotides combined with low-dose cyclophosphamide
47. Rational approaches to design of therapeutics targeting molecular markers
48. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins
49. bcl-2 gene family and the regulation of programmed cell death
50. Antisense bcl-2 treatment increases programmed cell death in non-small cell lung cancer cell lines
51. The mononucleotide-dependent, nonantisense mechanism of action of phosphodiester and phosphorothioate oligonucleotides depends upon the activity of an ecto-5′-nucleotidase
52. CpG motifs in bacterial DNA and their immune effects
53. CpG motifs in bacterial DNA trigger direct B-cell activation
54. Antisense - Time to shoot the messenger
55. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of EBV-associated lymphoproliferative disease to rituximab
56. Correlated expression of Bcl-2 protein, estrogen receptor, cathepsin D and low growth fraction (PCNA) in intracystic papillary breast carcinoma
57. Simultaneous detection of Bcl-2 protein, trisomy 12, retinoblastoma and p53 monoallelic gene deletions in B-cell chronic lymphocytic leukemia by fluorescence in situ hybridization (FISH): Relation to disease status
58. Differential sensitivity of MCF-7 and LCC2 cells, to multiple growth inhibitory agents: Possible relation to high bcl-2/bax ratio?
59. Circadian rhythms of Bcl-2 and Bax protein expressions in mouse bone marrow
60. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin
61. Combination of bcl-2 antisense oligodeoxynucleotide (G3139), p-glycoprotein inhibitor (PSC833) and liposomal doxorubicin can suppress the growth of drug-resistant human breast cancer xenografts in SCID mice
62. Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts
63. Significant disease response to Genasense™ (G3139, Genta), a Bcl-2 antisense, in combination with chemotherapy in refractory or relapsed acute leukemia: A phase I study
64. Progression from lymphoid hyperplasia to high grade malignant lymphoma in mice transgenic for the t(14;18)
65. Randomized phase III study of temozolomide versus decarbazine in the treatment of patients with advanced metastatic malignant melanoma
66. A unique mechanism regulating gene expression: Translational inhibition by a complementary RNA transcript (micRNA)
67. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase
68. Phase I trial of bcl-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer
69. A phase I/IIA dose-escalating trial of bcl-2 antisense (G3139) treatment by 14-day continuous intravenous infusion (CI) for patients with androgen-independent prostate cancer or other advanced solid tumor malignancies
70. Targeted distribution of Bcl-2αβ in mice: Occurrence of gray hair, polycystic kidney disease, and lymphocytopenia
71. From bench to clinic with apoptosis-based therapeutic agents
72. Sequence dependent interaction of bcl-2 targeted antisense oligodeoxynucleotides (AS-ODN) with chemotherapy in human DoHH2 non-Hodgkin's lymphoma (NHL) cells
73. Bcl-2 antisense (Genasense™) as monotherapy for patients with refractory chronic lymphocytic leukemia
74. A phase I, pharmacokinetic, and biologic correlative study of G3139 and irinotecan (CPT-11) in patients with metastatic colorectal cancer
75. G3139 downregulates the expression of bcl-2 in patients with metastatic colorectal cancer treated with irinotecan (CPT-11)
76. Regulation of clinical chemoresistance by Bcl-2 and Bax oncoproteins in B-cell chronic lymphocytic leukaemia
77. Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia
78. Estrogen withdrawal-induced human breast cancer tumour regression in nude mice is prevented by Bcl-2
79. Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy
80. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice
81. Warner-Lambert/Parke-Davis award lecture. Mechanisms of apoptosis
82. Dysregulation of apoptosis in cancer
83. Promise and problems of Bcl-2 antisense therapy
84. Bcl2-mediated tumorigenicity of a human T-lymphoid cell line: Synergy with MYC and inhibition by Bcl-2 antisense
85. Regulation of chemoresistance by the Bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines
86. Antisense-mediated inhibition of bcl-2 proto-oncogene expression and leukemic cell growth and survival: Comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides
87. A phase I/II trial of Genasense and paclitaxel in chemorefractory small cell lung cancer
88. Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells
89. A phase I trial of G3139 (Genta, Inc.), a BCL2 antisense drug, by continuous infusion (CI) as a single agent and with weekly taxol (T)
90. Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice
91. Genetic analysis of chemoresistance in primary murine lymphomas
92. Increased sensitivity of prostate cancer cells to radiation by the down-regulation of bcl2
93. Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines
94. Involvement of Bcl-2 and Bax in photodynamic therapy-mediated apoptosis. Antisense Bcl-2 oligonucleotide sensitizes RIF 1 cells to photodynamic therapy apoptosis
95. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide
96. The expression of drug resistance gene products during the progression of human prostate cancer
97. Antisense therapy in oncology: New hope for an old idea?
98. G3139 (Bcl-2 antisense oligonucleotide) is active against Gleevec-resistant Bcr-Abl-positive cells
99. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving bcl-2 proto-oncogene expression in human breast cancer cells
100. Bcl-2 plays a critical role in growth and in spontaneous or induced apoptosis in myeloma cell lines: A study with inducible bcl-2 transfection constructs
101. Novel compounds in the therapy of breast cancer: Opportunities for integration with docetaxol
102. Downregulation of bcl-2 expression by antisense-oligonucleotide (AS-ODN) treatment enhances mitoxantrone cytotoxicity in the androgen-dependent Shionogi tumor model
103. G3139 (Genasense™) enhances docetaxol antitumor activity and leads to long-term survivors in the androgen-independent prostate cancer xenograft (PC3) model
104. Apoptotic induction in transformed follicular lymphoma cells by Bcl-2 downregulation
105. Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis
106. Evaluation of bcl-2 antisense oligonucleotide drugs in multiple myeloma
107. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair
108. Combination of G3139 (Genasense™), a Bcl-2 antisense oligonucleotide, with docetaxel (Taxotere®) is active in a murine xenograft model of human non-small cell lung cancer
109. Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model
110. Bcl-2 antisense therapy prolongs survival of gastric cancer in SCID mice
111. Anti-tumor effect of G3139 Bcl-2 antisense oligonucleotide (Genasense™) is not mediated by immune stimulation in SCID mice
112. Bcl-2 antisense oligodeoxynucleotide (ODN) (G3139) therapy exerts its antitumor action through a sequence-specific antisense effect, and not a cell-mediated immune response
113. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma
114. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma
115. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization
116. Ribonucleases H of retroviral and cellular origin
117. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma
118. Accelerated disappearance of melanocytes in bcl-2-deficient mice
119. Tumor regression of human breast carcinoma by combination therapy of anti-bcl-2 antisense oligonucleotide and chemotherapeutic drugs
120. Molecular thanatopsis: A discourse on the Bcl2 family and cell death
121. The role of bcl-2 in the progression of the colorectal adenomacarcinoma sequence
122. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide
123. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines
124. Plasma and serum-protein binding of antisense oligodeoxynucleotide phosphorothioates in experimental animals and humans